期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

CA19-9在胰腺癌诊断中的临床价值 被引量：4

原文传递
导出
摘要 胰腺癌是临床上较常见的消化道肿瘤,恶性程度极高,且发病率不断上升.由于其起病隐匿、早期缺乏特异性症状及胰腺隐蔽的解剖位置,大多数患者在获得确诊时已经出现局部侵犯或远处转移,从而失去了根治性手术的机会[1].糖类抗原19-9（Carbohydrate antigen 19-9,CA19-9）是目前临床上应用最多,也是价值最高的胰腺癌肿瘤标志物.CA19-9最早应用于胰腺癌的诊断,近年来越来越多的临床研究显示其在胰腺癌的术前评估、治疗监测及预后等多个方面显示出较高的价值.作为一种经典的肿瘤标志物,CA19-9不断显示出在胰腺癌诊断中的价值.
作者 陈炯 陈龙江
机构地区 安徽医科大学附属省立医院普外科
出处 《国际外科学杂志》 2013年第6期364-366,共3页 International Journal of Surgery
基金 国家自然科学基金资助项目（No.81071985） 安徽省国际科技合作计划项目（No.1008010038） 安徽省科技攻关计划资助项目（No.110104022172）
关键词 CA19-9 临床价值 胰腺癌 诊断 肿瘤标志物 消化道肿瘤 根治性手术 恶性程度
分类号 R735.9 [医药卫生—肿瘤]
  • 相关文献

参考文献15

  • 1Hailer DG. New perspectives in the management of pancreas canc- er[J]. Semin Oncol, 2003, 30(4 Supp 11) : 3-10.
  • 2Goonetilleke KS, Siriwardena AK. Systematic review of carbohy- drate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer [ J]. Eur J Surg Oneol, 2007, 33 (3) : 266-270.
  • 3Duraker N, Hot S, Polat Y, et al. CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic dis- eases with or without jaundice [ J ]. J Surg Oncol, 2007, 95 (2) : 142-147.
  • 4汤厚阔,陈炯.肿瘤标志物CA19-9、CA242、CEA和CA125联合检测在胰腺癌诊断中的意义[J].肝胆胰外科杂志,2009,21(2):95-97. 被引量：30
  • 5王伟林,吴泽晖,朱峰,孙强,尉建锋,叶松,郑树森.CA19-9在影像学检查疑似胰腺癌病人诊断中的价值[J].中国实用外科杂志,2013,33(2):137-139. 被引量：10
  • 6Kim YC, Kim HJ, Park JH, et al. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic ade- nocarcinoma[J]. J Gastroenterol Hepatol, 2009, 24(12): 1869- 1875.
  • 7Hartwig W, Strobel O, Hinz U, et al. CA19-9 in potentially re- sectahle pancreatic cancer: perspective to adjust surgical and perio- perative therapy I J]. Ann Surg Oncol, 2012, [ Epub ahead of print ].
  • 8Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal [ J ]. J Gastrointest Oncol, 2012, 3(2) : 105-119.
  • 9任师颜,张文智,董家鸿,周宁新,黄晓强,黄志强.CA19-9对胰腺癌手术可切除性的预测价值[J].肝胆外科杂志,2008,16(3):187-190. 被引量：14
  • 10Sugiura T, Uesaka K, Kanemoto H, et al. Serum CA19-9 is a sig- nificant predictor among preoperative parameters for early recur- rence after resection of pancreatic adenocarcinoma[ J]. J Gastroint- est Surg, 2012, 16(5) : 977-985.

二级参考文献36

  • 1Liao, Quan,Zhao, Yu-Pei,Yang, Ying-Chi,Li, Li-Jun,Long, Xiao,Han, Shao-Mei.Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head[J].Hepatobiliary & Pancreatic Diseases International,2007,6(6):641-645. 被引量：27
  • 2王春友,陶京.现代影像学技术对胰腺癌的诊断价值及选择[J].中国实用外科杂志,2004,24(11):654-655. 被引量：6
  • 3Aapro MS, Martin C, Hatty S. Gemeitabine-a safety review [J]. Anticancer Drugs, 1998,9(3) : 191-201.
  • 4Burris HA 3rd, Moore M J, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial [Jl. J Clin Oncol, 1997,15(6):2403-2413.
  • 5Sail F, Roscher R, Beger HG. Tumor markers in pancreatic cancer: Sensitivity and specificity of CA 19-9 [J]. Hepatogastroenterology, 1989,36(6) : 419-423.
  • 6Halm U, Rohde N, Klapdor R, et al. Improved sensitivity of fuzzy logic based tumor marker profiles for diagnosis of pancreatic carcinoma versus benign pancreatic disease [J]. Anticancer Res, 2000,20(6D) :4957-4960.
  • 7Ueno H, Okusaka T, Ikeda M, et al. Phase II study of combination chemotherapy with gemcitabine and cisplatin for patients with metastatic pancreatic cancer [J]. Jpn J Clin Oncol, 2007,37 : 515-520.
  • 8Baize N, Abu Shalaa A, Berthier F, et al. Gemcitabine combined with oxaliplatin is safe and effective in patients with previously untreated advanced pancreatic adenocarcinoma [J]. Gastroenterol Clin Biol, 2005,29(10) : 1006-1009.
  • 9Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer : a randomized, multicenter, phase Ⅲ trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group [J]. J Clin Oncol, 2007,25 ( 16 ) : 2212-2217.
  • 10Endlicher E, Troppmann M, Kullmann A, et al. Irinotecan plus gemcitabine and 5-fluorouracil in advanced pancreatic cancer: a phase II study [J]. Oncology, 2007,72(5-6):279- 284.

共引文献55

同被引文献22

  • 1朱康民,何尚浦.病例对照研究中相对危险度的估计方法及其应用[J].中国卫生统计,1989,6(1):25-28. 被引量：2
  • 2Gui J C, Yan W L, Liu X D. CA19-9 and CA242 as tumor markers for the diagnosis of pancreatic cancer: a meta-analysis [ J ]. Clin Exp Med, 2014,14 ( 2 ) : 225-233.
  • 3Yue T, Partyka K, Maupin K A, et al. Identification of blood-protein carriers of the CA 19-9 antigen and charac- terization of prevalence in pancreatic diseases [ J ]. Pro- teomics, 2011,11 ( 18 ) : 3665-3674.
  • 4Galli C, Basso D, Plebani M. CA19-9: handle with care [J]. Clin Chem Lab Med, 2013,51(7) :1369-1383.
  • 5Sak M E, Evsen M S, Soydine H E, et al. Imperforate hymen with elevated serum CA125 and CA19-9 levels [ J ]. J Reprod Med, 2013,58 ( 1-2 ) :47-50.
  • 6Shin J Y, Yoo S J, Park B M, et al. Extremely increased serum carbohydrate antigen 19-9 levels caused by new or resistant infections to previous antibiotics in chronic lung diseases [ J ]. Tubere Respir Dis, 2013,75 ( 3 ) : 125-127.
  • 7Bertino G I, Ardiri A M, Calvagno G S, et al. Carbohy- drate 19-9 antigen serum levels in liver disease[ J]. Bi- oMed Res Int, 2013,2013:531640.
  • 8Elisei R, Lorusso L, Romei C, et al. Medullary thyroid cancer secreting carbohydrate antigen 19-9 (CA19-9) : a fatal case report[ J]. J Clin Endoerinol Metab, 2013,98 (9) :3550-3554.
  • 9Onal C, Colakoglu T, Ulusan S N, et al. Biliary obstruc- tion induces extremely elevated serum CA19-9 levels: case report[ J ]. Onkologie, 2012,35 ( 12 ) :780-782.
  • 10Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015 [ J]. CA Cancer J Clin, 2015, 65 ( 1 ) : 5-29. DOI : 10. 3322/caac. 21254.

引证文献4

二级引证文献11

国际外科学杂志
2013年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部